JPS62266056A - Viscoelastic solution for ophthalmic operation - Google Patents

Viscoelastic solution for ophthalmic operation

Info

Publication number
JPS62266056A
JPS62266056A JP61110160A JP11016086A JPS62266056A JP S62266056 A JPS62266056 A JP S62266056A JP 61110160 A JP61110160 A JP 61110160A JP 11016086 A JP11016086 A JP 11016086A JP S62266056 A JPS62266056 A JP S62266056A
Authority
JP
Japan
Prior art keywords
solution
molecular weight
concentration
average molecular
group content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP61110160A
Other languages
Japanese (ja)
Other versions
JPH0657245B2 (en
Inventor
三宅 謙作
厚 河合
智 橋本
薫 神谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TOME SANGYO KK
Original Assignee
TOME SANGYO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TOME SANGYO KK filed Critical TOME SANGYO KK
Priority to JP61110160A priority Critical patent/JPH0657245B2/en
Publication of JPS62266056A publication Critical patent/JPS62266056A/en
Publication of JPH0657245B2 publication Critical patent/JPH0657245B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Materials For Medical Uses (AREA)

Abstract

(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。
(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

【発明の詳細な説明】 〔利用分野〕 本発明は、眼科手術時に用いられる粘稠剤である眼科手
術用粘弾性溶液に関する。
DETAILED DESCRIPTION OF THE INVENTION [Field of Application] The present invention relates to a viscoelastic solution for ophthalmic surgery, which is a thickening agent used during ophthalmic surgery.

本発明の眼科手術用粘弾性溶液は、とりわけ白内障手術
、眼内レンズ挿入手術、角膜移植手術、その他眼科手術
時に前房や後戻の水晶体カプセル内などに注入し、角膜
内皮の保護、前房水の形成、後房水の形成などをはかる
ために利用できる。
The viscoelastic solution for ophthalmic surgery of the present invention can be injected into the anterior chamber or retrograde lens capsule during cataract surgery, intraocular lens insertion surgery, corneal transplantation surgery, and other ophthalmic surgeries, to protect the corneal endothelium and protect the anterior chamber. It can be used to measure the formation of water, posterior aqueous humor, etc.

(従来技術とその問題点〕 従来より、白内障手術、眼内レンズ挿入手術、角膜移植
手術、眼外傷牟術、緑内障手術時に角膜内皮細胞などの
M+織を器具からの保護したり、前房空間を保持したり
、その他の目的で1%ヒアルロン酸ナトリウム溶液が使
われている。しかし、ヒアルロン酸ナトリウムは、鶏冠
等から抽出する天然物であるため高価であり、さらに精
製が難しく、滅菌も歎しいために極めて高価なものとな
っている。また安定性も不良で変質しゃずいという問題
点もあった。
(Prior art and its problems) Conventionally, during cataract surgery, intraocular lens insertion surgery, corneal transplant surgery, ocular trauma surgery, and glaucoma surgery, M+ tissues such as corneal endothelial cells are protected from instruments, and the anterior chamber space is A 1% sodium hyaluronate solution is used to preserve the water and for other purposes.However, sodium hyaluronate is a natural product extracted from cockscombs, etc., so it is expensive, difficult to purify, and difficult to sterilize. This makes it extremely expensive, and there is also the problem of poor stability and deterioration.

コンドロイチン硫酸の使用も試みられているが、粘稠性
を高めるには、20%程度の高濃度を必要とするため、
浸透圧が上昇して角膜の膨潤を来すという問題があった
The use of chondroitin sulfate has also been attempted, but it requires a high concentration of about 20% to increase viscosity.
There was a problem in that the osmotic pressure increased and the cornea swelled.

一方、より安価な粘性物質として、セルロースエーテル
溶液の使用が試みられている。セルロースエーテルとし
ては、メチルセルロースまたはヒドロキシプロピルメチ
ルセルロースなどが用いられている。しかし従来使われ
ているのは、重量平均分子1i400000以下、濃度
1〜2.5%の溶液であり、このものは粘度が十分でな
く、手fli適性はヒアルロン酸ナトリウムに比べて劣
るものであった。そこで粘度を高めるために濃度を高め
ると濾過が困難となって製剤化できず、また分子量を高
めると、眼圧の上昇等を招くといったような問題点があ
り、実用化が困難であった。
On the other hand, attempts have been made to use cellulose ether solutions as cheaper viscous substances. As the cellulose ether, methylcellulose or hydroxypropylmethylcellulose is used. However, what has been conventionally used is a solution with a weight average molecular weight of less than 1i400,000 and a concentration of 1 to 2.5%, which does not have sufficient viscosity and is inferior to sodium hyaluronate in its suitability for manual handling. Ta. Therefore, if the concentration is increased to increase the viscosity, filtration becomes difficult and formulation cannot be made, and if the molecular weight is increased, there are problems such as an increase in intraocular pressure, making it difficult to put it into practical use.

〔問題点を解決するための手段〕[Means for solving problems]

そこで本発明者らは、鋭意研究を重ねた結果、次のよう
な特定の組成、分子量、分子量分布、濃度を有するヒド
ロキシプロピルメチルセルロース溶液を用いることによ
り、安価であり、製剤化が容易で高粘性を有し、眼圧の
上昇等の障害もなく、ヒアルロン酸ナトリウムと同等以
上の効果を出し得ることを見出した。
As a result of intensive research, the present inventors have found that by using a hydroxypropyl methylcellulose solution having the following specific composition, molecular weight, molecular weight distribution, and concentration, it is possible to create a solution that is inexpensive, easy to formulate, and has a high viscosity. It has been found that it has the same or higher effect as sodium hyaluronate without causing any problems such as increased intraocular pressure.

すなわち本発明は、メトキシ基含量28〜32%、ヒド
ロキシプ1コボキシ基含M7〜12%で、重量平均分子
量(M、、)420000〜800000、数平均分子
量(MN)に対する重量平均分子量の比(M、、/MN
 )5.5以下のヒドロキシプロピルメチルセルロース
を次式に規定される濃度範囲、 最大濃度の自然対数: ffogc14Ag  =0. 64  0. 005
5M最小濃度の自然対数: NOgCM+N=0.57 0.0071Mになるよう
に塩類を含有する水に溶解した眼科手術用粘弾性溶液を
提供するものである。
That is, the present invention has a methoxy group content of 28 to 32%, a hydroxyl group content of 7 to 12%, a weight average molecular weight (M) of 420,000 to 800,000, and a ratio of the weight average molecular weight to the number average molecular weight (MN) ( M,,/MN
) 5.5 or less hydroxypropyl methyl cellulose in the concentration range defined by the following formula, natural logarithm of maximum concentration: ffogc14Ag = 0. 64 0. 005
A viscoelastic solution for ophthalmic surgery is provided which is dissolved in water containing saline such that the natural logarithm of the minimum concentration of 5M is: NOgCM+N=0.57 0.0071M.

また望ましくは、ヒドロキシプロピルメチルセルロース
の溶液濃度がおよそ0.02%の場合において、電気抵
抗法によって測定した2μm以」−の微粒子数が250
0個/ m 1以下、4ttm以上の微粒子数が20個
/m1以下である眼科手術用粘弾性溶液を提供するもの
である。
Preferably, when the solution concentration of hydroxypropyl methyl cellulose is approximately 0.02%, the number of fine particles of 2 μm or larger measured by an electrical resistance method is 250.
The present invention provides a viscoelastic solution for ophthalmologic surgery in which the number of fine particles of 4 ttm or more is 20 particles/m1 or less.

本発明におけるヒドロキシプロピルメチルセルロースに
ついて、以下に説明する。
Hydroxypropyl methylcellulose in the present invention will be explained below.

ヒドロキシプロピルメチルセルロースは、メトキシ基含
量が28〜32%、ヒ10キシプロポキシ基含量が7〜
12%であるのが好ましい。
Hydroxypropyl methylcellulose has a methoxy group content of 28 to 32% and a hydroxypropoxy group content of 7 to 32%.
Preferably it is 12%.

メトキシ基含量が28%より低いと、溶解性が低下する
ために、溶液中の微粒子(ミクロゲル)が多くなり、製
剤時の濾過性に劣ることになる。
If the methoxy group content is lower than 28%, solubility decreases, resulting in an increase in the number of fine particles (microgel) in the solution, resulting in poor filterability during formulation.

また、微粒子(ミクロゲル)が残留した場合は、眼圧上
昇の障害を起こす。メトキシ基含量が32%以」−にな
ると、親水性が不十分点なり好ましくない。ヒドロキシ
プロポキシ基台Mが7%より低い場合、溶液中の微粒子
(ミクロゲル)が多くなり、濾過性が不良となる。また
、細管内の溶液の流動性が不良となるために、注射器か
らの押し出しが困難となり、実用性に乏しくなる。ヒド
ロキシプロポキシ基含量が12%以上のものは合成が難
しい。
Furthermore, if fine particles (microgel) remain, they cause problems such as increased intraocular pressure. If the methoxy group content is 32% or more, the hydrophilicity is insufficient, which is not preferable. When the hydroxypropoxy base M is lower than 7%, the number of fine particles (microgel) in the solution increases, resulting in poor filterability. Furthermore, since the fluidity of the solution in the capillary becomes poor, it becomes difficult to extrude it from a syringe, making it impractical. It is difficult to synthesize those with a hydroxypropoxy group content of 12% or more.

重量平均分子量(M8)は、42QOOO〜8oooo
oの範囲にあるのが好ましい。
Weight average molecular weight (M8) is 42QOOOO~8oooo
It is preferably in the range of o.

重量平均分子量は、たとえばウベローデ型粘度計を用い
て固有粘度〔η〕を測定し、次式からMwを求める。
The weight average molecular weight is determined by measuring the intrinsic viscosity [η] using, for example, an Ubbelohde viscometer, and calculating Mw from the following formula.

〔η)  −3,67X I  O−’Mtn  ’−
”重量平均分子量が420000より低い場合、溶液の
粘度が十分に高くなく、眼科手術用粘弾性溶液としての
用途が限定される。また溶液の粘度を高めようとして濃
度を高めると、濾過が著しく困難となり、製剤化ができ
ない。
[η) -3,67X I O-'Mtn'-
``If the weight average molecular weight is lower than 420,000, the viscosity of the solution is not high enough, and its use as a viscoelastic solution for ophthalmic surgery is limited.Furthermore, if the concentration is increased in an attempt to increase the viscosity of the solution, filtration becomes extremely difficult. Therefore, it cannot be formulated into a formulation.

重量平均分子量が800000を越えると、眼圧の上昇
を起こし易く、また前房等に残留する時間が長くなった
り、前房等からの洗い出し易さが低下するなどの点で好
ましくない。特に望ましいのは500000〜7000
00である。
If the weight average molecular weight exceeds 800,000, it is undesirable because it tends to cause an increase in intraocular pressure, the time it remains in the anterior chamber etc. becomes longer, and the ease with which it is washed out from the anterior chamber etc. decreases. Particularly desirable is 500,000 to 7,000.
It is 00.

数平均分子’ft (MN>に対する重量平均分子量(
M、4)の比(M、/MN )は、5.5以下であるの
が好ましい。
Weight average molecular weight ( for number average molecule 'ft (MN>)
The ratio (M,/MN) of M, 4) is preferably 5.5 or less.

数平均分子量(MN)に対する重量平均分子量(M、)
の比(M、/MN)は、ゲルパーミェーションクロマト
グラフィー(GPC)により求めることができる。ただ
し本発明では、カラムはTS K gel G M P
 Wxt (東洋曹達社製)2本を用いて、試料は0.
02%NaN3含有0.1MNa。
Weight average molecular weight (M, ) to number average molecular weight (MN)
The ratio (M, /MN) can be determined by gel permeation chromatography (GPC). However, in the present invention, the column is TS K gel G M P
Using two Wxt (manufactured by Toyo Soda Co., Ltd.), the sample was 0.
0.1M Na containing 02% NaN3.

SO,水溶液とし、流速1 m 127m1n 、 温
度25℃として測定し、平均分子量を求めた。
SO was made into an aqueous solution and measured at a flow rate of 1 m 127 m1n and a temperature of 25°C to determine the average molecular weight.

重量平均分子量が420000以」二で且っM。The weight average molecular weight is 420,000 or more.

/MNが5.5を越えると、溶液の濾過性が不良となり
、また眼圧の上昇を来す傾向となる。なぜならば、M、
l/MNが大となった場合、同一重量平均分子量でもM
11/MNが小の場合と比較してより高分子量部分が多
く存在するため、濾過性の不良および眼圧の上昇を招く
ものと考えられる。
When /MN exceeds 5.5, the filterability of the solution becomes poor and the intraocular pressure tends to increase. Because, M.
When l/MN becomes large, even if the weight average molecular weight is the same, M
This is thought to result in poor filtration and increased intraocular pressure, since more high molecular weight moieties are present than in the case where 11/MN is small.

特に望ましいのは5.2以下である。Particularly desirable is 5.2 or less.

ヒドロキシプロピルメチルセルロースは次式に規定され
る濃度範囲、 最大濃度の自然対数: 10gCHAx =0.64 0.0055M最小濃度
の自然対数: 10gCs+N=0. 57 0. 0071Mになる
ように塩類を含有する水に溶解するのが好ましい。
Hydroxypropyl methylcellulose has a concentration range defined by the following formula: Natural logarithm of maximum concentration: 10gCHAx = 0.64 0.0055M Natural logarithm of minimum concentration: 10gCs+N=0. 57 0. It is preferable to dissolve it in water containing salts so that it becomes 0.0071M.

最大濃度(C)IAや、%)を越えると眼圧の上昇を来
たし、前房等における残留時間が長くなったり、手術終
了後洗い出しにくくなるなどの点で好ましくない。
If the maximum concentration (C)IA or %) is exceeded, the intraocular pressure increases, the residual time in the anterior chamber becomes longer, and it becomes difficult to wash out after the surgery, which is undesirable.

最小濃度(C1lI8、%)以下の場合は、溶液粘度が
低下し、眼科手術用粘弾性溶液としての用途が著しく限
定される。
If the concentration is below the minimum concentration (C1lI8, %), the viscosity of the solution decreases, and its use as a viscoelastic solution for ophthalmic surgery is significantly limited.

上記4つの用件、つまりヒドロキシプロピルメチルセル
ロースのメトキシ基含量、ヒドロキシプロポキシ基含量
、平均分子量、分子量分布および濃度範囲が全部溝たさ
れる場合に限って、■ 製剤化を容易にし、 ■ 眼圧の上昇を抑制し、 ■ 前房中や後戻中の残留時間を縮小して、且つ洗い出
し易くし、 ■ 眼科手術用粘弾性溶液として有効な高粘度とする などの目的を達成することができる。
Only when the above four requirements, namely methoxy group content, hydroxypropoxy group content, average molecular weight, molecular weight distribution, and concentration range of hydroxypropyl methylcellulose are all met, can the formulation be easily formulated; and ■ reduce intraocular pressure. It is possible to achieve the following objectives: (1) reducing the residual time in the anterior chamber and during retroversion and making it easier to wash out; and (2) providing a high viscosity that is effective as a viscoelastic solution for ophthalmic surgery.

ヒドロキシプロピルメチルセルロースは上記のように規
定した溶解性の優れたものを用いるが、微粒子数を特定
個数以下とすることが、眼圧の」−昇なとの障害を起こ
さないために必要である。望ましくは、ヒドロキシプロ
ピルメチルセルロースの溶液濃度がおよそ0.02%の
場合において、電気抵抗法によって測定した2μm以」
−の微粒子数が2500個7m1l以下、4μm以上の
微粒子数が20個/、n以下であるのが好ましい。
Hydroxypropyl methylcellulose having excellent solubility as defined above is used, but it is necessary to keep the number of fine particles below a certain number in order to avoid problems such as an increase in intraocular pressure. Preferably, when the solution concentration of hydroxypropyl methyl cellulose is approximately 0.02%, the diameter is 2 μm or more as measured by an electrical resistance method.
- It is preferable that the number of fine particles of 2500 pieces/7ml or less, and the number of fine particles of 4 μm or more is 20 pieces/n or less.

溶液中の微粒子の数は、本発明ではCoulterE 
Iectronics  T N C、社製のCoul
ter  Count−erTA−H型を用い、電気抵
抗法により測定した。ヒドロキシプロピルメチルセルロ
ース溶液は、生理食塩水で希釈し、0.02%として測
定する。
In the present invention, the number of microparticles in a solution is determined by CoulterE.
Coul manufactured by Electronics TNC, Inc.
It was measured by an electrical resistance method using a ter Count-erTA-H type. The hydroxypropyl methylcellulose solution is diluted with saline and measured as 0.02%.

アパチャーは50μmを用いる。アパチャーを溶液がi
i!1通ずる時、粒子が存在すると両側の電極の間の電
気抵抗に変化を生じ、これを検出して粒子ザイズを求め
ることができる。
An aperture of 50 μm is used. When the aperture is
i! When a particle is present, a change occurs in the electrical resistance between the electrodes on both sides, and this can be detected to determine the particle size.

Coulter  Counterにより求める微粒子
数は、2μm以上のものが2500個/m7!以下、4
μm以上のものが20個/ m I!である必要があり
、これ以上の場合には、眼圧」1昇などの障害が起こり
やすい。
The number of particles determined by Coulter Counter is 2,500 particles/m7 of particles larger than 2 μm! Below, 4
20 pieces/m I! If the amount is higher than this, problems such as an increase in intraocular pressure by 1% are likely to occur.

微粒子数を減少させるためには、通常0.8μmのメン
ブレンフィルターで濾過を繰り返すことが好ましく、2
回乃至5回の濾過が好ましい。
In order to reduce the number of fine particles, it is usually preferable to repeat filtration using a 0.8 μm membrane filter.
Preferably, filtration is carried out 5 times to 5 times.

〔発明の効果〕〔Effect of the invention〕

本発明の眼科手44テ用粘弾性?fI液は、以下のよう
な効果を有する。
Viscoelasticity for 44 ophthalmological hands of the present invention? fI liquid has the following effects.

(1)  ヒアルロン酸ナトリウムに対しては、■ 極
めて安価である。
(1) Compared to sodium hyaluronate, ■ It is extremely inexpensive.

■ 化学的に安定で、熱、光などの影響を受けに<<、
オートクレーブ滅菌が可能である。
■ Chemically stable and unaffected by heat, light, etc.
Autoclave sterilization is possible.

■ 等張化剤が自由に選択できる。■Tonicity agent can be freely selected.

■ 眼科手術用粘弾性溶液としての臨床的効果は同等以
上である。
■ The clinical effect is equivalent or better than that of a viscoelastic solution for ophthalmic surgery.

等の効果が認められる。The following effects were observed.

(2)従来のメチルセルロースまたはヒドロキシプロピ
ルメチルセルロースなどに対しては、■ 従来のメチル
セルロースまたはヒドロキシプロピルメチルセルロース
からなる製剤と比較して高粘度であるため、眼科手術用
粘弾性溶液として用いる場合、前房等の形成能力、眼内
レンズの挿入の容易さなどの点で著しく優れる。
(2) Conventional methylcellulose or hydroxypropylmethylcellulose, etc., have a higher viscosity than preparations made of conventional methylcellulose or hydroxypropylmethylcellulose, so when used as a viscoelastic solution for ophthalmic surgery, it is difficult to It is extremely superior in terms of forming ability and ease of inserting intraocular lenses.

特にin the bag方式の眼内レンズ挿入の場合
、従来のメチルセルロースまたはヒドロキシプロピルメ
チルセルロースからなる製剤では困難であった手術が可
能となる。また構造粘性も大きいため、高粘度である割
に、注射針からの押し出しが容易である。
Particularly in the case of in-the-bag intraocular lens insertion, surgery that is difficult to perform with conventional preparations made of methylcellulose or hydroxypropylmethylcellulose becomes possible. Furthermore, since it has a high structural viscosity, it is easy to extrude from an injection needle despite its high viscosity.

■ 眼圧、前房内の残留時間、前房からの洗い出し易さ
などの安全性は従来のメチルセルロースまたはヒドロキ
シプロピルメチルセルロースからなる製剤と同等である
■Safety such as intraocular pressure, residence time in the anterior chamber, and ease of washing out from the anterior chamber is equivalent to conventional preparations made of methylcellulose or hydroxypropylmethylcellulose.

等の効果が認められる。The following effects were observed.

したがって、本発明の眼科手術用粘弾性溶液は、とりわ
け白内障手術、眼内レンズ挿入手術、角膜移植手術、そ
の他眼科手術時に前房や後戻の水晶体カプセル内などに
注入し、角膜内皮の保護、前房の形成、後戻の形成など
をはかるために極めて有効に利用することができる。
Therefore, the viscoelastic solution for ophthalmic surgery of the present invention can be injected into the anterior chamber or retrograde lens capsule during cataract surgery, intraocular lens insertion surgery, corneal transplantation surgery, and other ophthalmic surgeries to protect the corneal endothelium. It can be used extremely effectively to measure the formation of the anterior chamber, the formation of retrogression, etc.

〔実施例〕〔Example〕

以下に実施例を以て、本発明を更に詳細に説明するが、
本発明はこれら実施例のみに限定されるものではない。
The present invention will be explained in more detail with reference to Examples below.
The present invention is not limited only to these examples.

実施例1 メトキシ基含量29.5%、ヒドロキシプロポキシ基含
量10.6%、重量平均分子量?20000、Mw /
 MN = 4.5のヒドロキシプロピルメチルセルロ
ース(信越化学■製)を生理食塩水に溶解し、1.8%
の溶液を調製した。これを0゜8μmのメンブレンフィ
ルターを用いて3回濾過を繰り返した。得られた溶液の
20℃における粘度(B型粘度計、回転数12rpmに
よる)は、20900cpsであった。
Example 1 Methoxy group content 29.5%, hydroxypropoxy group content 10.6%, weight average molecular weight? 20000, Mw /
Hydroxypropyl methylcellulose (manufactured by Shin-Etsu Chemical) with MN = 4.5 was dissolved in physiological saline to give a concentration of 1.8%.
A solution was prepared. This was repeatedly filtered three times using a 0°8 μm membrane filter. The viscosity of the obtained solution at 20° C. (by a B-type viscometer, rotation speed 12 rpm) was 20,900 cps.

この溶液を用い、摘出豚眼の眼圧を高めた状態で、in
 the bag方式による後戻眼内レンズ挿入試験を
行ったところ、後戻形成能力が優れ、レンズの挿入は容
易であった。
Using this solution, in a state where the intraocular pressure of the isolated pig eye was increased,
When a retrograde intraocular lens insertion test using the bag method was performed, the retrograde formation ability was excellent and the lens insertion was easy.

比較例1  <ヒドロキシプロピルメチルセルロースの
濃度が低い場合) 実施例1と同様のヒドロキシプロピルメチルセルロース
の1.1%生理食塩水溶液を調製し、同様にして濾過し
た。得られた溶液の20℃における粘度は2010cp
sであった。この溶液を用い、実施例1と同様にして後
戻眼内レンズ挿入試験を行ったところ、後戻形成能力が
なく、レンズの挿入は困難であった。
Comparative Example 1 <When the concentration of hydroxypropyl methylcellulose is low) A 1.1% physiological saline solution of hydroxypropyl methylcellulose similar to that in Example 1 was prepared and filtered in the same manner. The viscosity of the obtained solution at 20°C is 2010 cp
It was s. Using this solution, a retrograde intraocular lens insertion test was conducted in the same manner as in Example 1. As a result, there was no retrograde formation ability, and lens insertion was difficult.

比1112   <ヒドロキシプロピルメチルセルロー
スの分子量が低い場合) メトキシ基含量29.6%、ヒドロキシプロポキシ基含
量10.8%、重量平均分子1g1o。
Ratio 1112 <When the molecular weight of hydroxypropyl methylcellulose is low) Methoxy group content 29.6%, hydroxypropoxy group content 10.8%, weight average molecule 1g1o.

00、Mw / MN = 6 、 2のヒドロキシプ
ロピルメチルセルロース(信越化学■製)を実施例1と
同様にして生理食塩水tこ溶解し、2.0%の溶液を調
製し、濾過した。得られた溶液の20℃における粘度は
、4010cpsであった。この溶液を用い、実施例1
と同様にして後房眼内レンズ挿入試験を行ったところ、
後戻形成能力が不十分で、レンズの挿入は困難であった
Hydroxypropyl methyl cellulose (manufactured by Shin-Etsu Chemical Co., Ltd.) having a concentration of 0.00 and Mw/MN = 6.2 was dissolved in physiological saline in the same manner as in Example 1 to prepare a 2.0% solution, which was filtered. The viscosity of the obtained solution at 20°C was 4010 cps. Using this solution, Example 1
When a posterior chamber intraocular lens insertion test was performed in the same manner as above,
Insertion of the lens was difficult due to insufficient retrograde ability.

実施例2 実施例1と同様のヒドロキシプロピルメチルセルロース
を生理食塩水に濃度1.6%となるように溶解し粘度(
20℃)11500cpsの溶液を調製した。これを0
.8μmのメンブレンフィルターで3kg/cm”の恒
圧で濾過したところ、第1図に示す如く1回目は目詰ま
りが生したが、2回目以降は容易に濾過可能で製剤上全
く問題がなっかた。
Example 2 The same hydroxypropyl methylcellulose as in Example 1 was dissolved in physiological saline to a concentration of 1.6%, and the viscosity (
20° C.) A solution of 11,500 cps was prepared. Set this to 0
.. When filtering with an 8 μm membrane filter at a constant pressure of 3 kg/cm, clogging occurred the first time as shown in Figure 1, but from the second time onwards, it was easy to filter and there were no problems with the formulation. .

比較例3  (ヒドロキシプロピルメチルセルロースの
分子量の低いものを濃度を高めることにより粘度を高め
る場合) 比較例2と同様のヒドロキシプロピルメチルセルロース
を生理食塩水に濃度2.9%となるように溶解し粘度(
20℃)11300cpsの溶液を調製した。この溶液
を実施例2と同様にして濾過したところ、第2図に示す
如く濾過回数を増加しても濾過性は全く向上せず、製剤
化が困難であっ実施例3 メトキシ基含量29.2%、ヒドロキシプロポキシ基含
量10.1%、重量平均分子量520000、Mw/M
N=4.9のヒドロキシプロピルメチルセルロース(信
越化学■製)を生理食塩水に溶解し、2.0%の溶液を
調製した。これを0゜8μmのメンブレンフィルターを
用いて3回濾過を繰り返した。得られた溶液の20℃に
おける粘度は、10100cpsであった。
Comparative Example 3 (Increasing the viscosity by increasing the concentration of hydroxypropyl methylcellulose with a low molecular weight) The same hydroxypropyl methylcellulose as in Comparative Example 2 was dissolved in physiological saline to a concentration of 2.9%, and the viscosity (
(20°C) 11,300 cps solution was prepared. When this solution was filtered in the same manner as in Example 2, as shown in Fig. 2, even if the number of filtrations was increased, the filtration performance did not improve at all, making it difficult to formulate a formulation.Example 3 Methoxy group content: 29.2 %, hydroxypropoxy group content 10.1%, weight average molecular weight 520000, Mw/M
Hydroxypropyl methylcellulose (manufactured by Shin-Etsu Chemical) with N=4.9 was dissolved in physiological saline to prepare a 2.0% solution. This was repeatedly filtered three times using a 0°8 μm membrane filter. The viscosity of the obtained solution at 20°C was 10,100 cps.

また、この溶液を生理食塩水で希釈して0.02%溶液
とし、Coulter  Counter  T A 
−TI型により50μmアパチャーを用いて測定した微
粒子は、2μm以上のものが933個/ m 1.4μ
m以上のものが16個/ll1pであった。家兎眼の前
房水を0.2m#吸引後、この溶液を0.2ml注入し
、眼圧を測定した。4時間f!13mn+Hgから25
mmHgへ眼圧上昇を見たが、問題となる程ではなく、
24時間後にはほぼ元の状態に回復した。
In addition, this solution was diluted with physiological saline to make a 0.02% solution, and the Coulter Counter T A
-The number of fine particles measured using a TI type using a 50 μm aperture was 933 particles/m of 2 μm or larger, 1.4 μm.
There were 16 pieces/ll1p of those with m or more. After suctioning 0.2 m# of anterior aqueous humor from a rabbit eye, 0.2 ml of this solution was injected, and the intraocular pressure was measured. 4 hours f! 13mn+Hg to 25
I saw an increase in intraocular pressure to mmHg, but it was not enough to cause a problem.
After 24 hours, it was almost back to its original state.

比較例4  (微粒子の多い場合) 実施例3と同様にして調製した溶液を1.2μmのメン
ブレンフィルターで1回濾過した。この溶液につき実施
例3と同様にして微粒子を測定したところ、2μm以上
のものが2830個/ml!、4μm以上のものが62
個/111であった。この溶液を実施例3と同様にして
家兎眼の前房に注入し、眼圧を測定したところ、4時間
後13mmHgから45mmHgまで眼圧上昇を示した
。この眼圧は24時間後にはほぼ元の状態に回復した。
Comparative Example 4 (When there are many fine particles) A solution prepared in the same manner as in Example 3 was filtered once with a 1.2 μm membrane filter. When the number of fine particles in this solution was measured in the same manner as in Example 3, the number of particles larger than 2 μm was 2830 particles/ml! , those with a diameter of 4 μm or more are 62
It was 111 pieces/111 pieces. This solution was injected into the anterior chamber of a rabbit's eye in the same manner as in Example 3, and the intraocular pressure was measured. After 4 hours, the intraocular pressure increased from 13 mmHg to 45 mmHg. This intraocular pressure returned to almost its original state after 24 hours.

比較例5   (ヒドロキシプロピルメチルセルロース
のメトキシ基含量の低い場合) メトキシ基含量21.2%、ヒドロキシプロポキシ基含
量6.7%、重量平均分子量570000、M、1/ 
MW = 4 、 7のヒドロキシプロピルメチルセル
ロース(信越化学卿製)を生理食塩水に溶解し、1.8
%の溶液を調製した。20℃における粘度は、1030
0cpsであった。得られた溶液を0.8μmのメンブ
レンフィルターで3kg/cI112の恒圧で濾過した
ところ、目詰まりがひどく濾過不可能であった。
Comparative Example 5 (When the methoxy group content of hydroxypropyl methyl cellulose is low) Methoxy group content 21.2%, hydroxypropoxy group content 6.7%, weight average molecular weight 570000, M, 1/
Hydroxypropyl methylcellulose (manufactured by Shin-Etsu Chemical Co., Ltd.) with MW = 4, 7 was dissolved in physiological saline, and 1.8
% solution was prepared. The viscosity at 20°C is 1030
It was 0 cps. When the obtained solution was filtered with a 0.8 μm membrane filter at a constant pressure of 3 kg/cI112, it was so clogged that filtration was impossible.

実施例4 および 比較例5  (ヒドロキシプロピルメチルセルロースの
分子量の低い場合) 眼内レンズ手術の際、眼内に注入したセルロースエーテ
ル溶液は潅流液で洗いだされる。この洗い出し易さを調
べるために次の実験を行った。
Example 4 and Comparative Example 5 (When the molecular weight of hydroxypropyl methylcellulose is low) During intraocular lens surgery, the cellulose ether solution injected into the eye is washed out with an irrigation solution. The following experiment was conducted to examine the ease of washing out.

2vallメスピペツトに試料溶液を2.0mj!吸い
込み内径しlのシリコーンチューブを装着し、マイクロ
チューブポンプで蒸留水を28 m Il/sinの速
度で20011n流し、出てきた溶液をビーカーに受け
、蒸発乾固し、セルロースエーテルの溶出量を定量して
残留量を求めた。その実験結果を第1表に示す。
Pour 2.0 mj of sample solution into a 2-vall volumetric pipette! Attach a silicone tube with a suction inner diameter of l, and flow distilled water for 20011n at a rate of 28 mIl/sin using a microtube pump, receive the solution in a beaker, evaporate to dryness, and quantify the elution amount of cellulose ether. The residual amount was determined. The experimental results are shown in Table 1.

ただし、実施例4では、実施例2と同一の溶液を試料溶
液として使用しく試料Aとする)、比較例5では、比較
例2と同一のヒドロキシプロピルメチルセルロースを生
理食塩水に2.5%濃度ニ溶解し、濾過したものを試料
溶液として使用した(試料Bとする)。
However, in Example 4, the same solution as in Example 2 was used as the sample solution (Sample A), and in Comparative Example 5, the same hydroxypropyl methylcellulose as in Comparative Example 2 was added to physiological saline at a concentration of 2.5%. The solution was dissolved and filtered and used as a sample solution (referred to as sample B).

第1表 この結果から、試料Aに比べて、試料Bは洗い出しに<
<、眼内に残留し易いことが分かる。
Table 1 From this result, compared to sample A, sample B has a less
<, it can be seen that it easily remains in the eye.

比較例6  (ヒドロキシプロピルメチルセルロースの
M。/M、Iが大きい場合) 2種のヒドロキシプロピルメチルセルロースをブレンド
することにより得たメトキシ基含量28゜9%、ヒドロ
キシプロポキシ基含量10.5%、重量平均分子量56
0000.M、/M、=6゜2のヒドロキシプロピルメ
チルセルロースt4理食塩水に溶解し、2.0%の溶液
を調製した。得られた溶液を0.8μmのメンブレンフ
ィルターで3回濾過した。20℃における粘度は、14
7QQcpsであった。実施例3、実施例4と同様にし
て家兎眼に注入し、眼圧を測定したところ、4時間後1
3nmHgから47mnHgまで眼圧上昇を示した。こ
の眼圧は24時間後にはほぼ元の状態に回復した。
Comparative Example 6 (When M./M, I of hydroxypropyl methylcellulose is large) Methoxy group content 28.9%, hydroxypropoxy group content 10.5%, weight average obtained by blending two types of hydroxypropyl methylcellulose. Molecular weight 56
0000. Hydroxypropyl methyl cellulose with M, /M, = 6°2 was dissolved in T4 saline to prepare a 2.0% solution. The resulting solution was filtered three times through a 0.8 μm membrane filter. The viscosity at 20°C is 14
It was 7QQcps. It was injected into the eyes of rabbits in the same manner as in Examples 3 and 4, and the intraocular pressure was measured.
Intraocular pressure increased from 3nmHg to 47mnHg. This intraocular pressure returned to almost its original state after 24 hours.

比較例1   (ヒドロキシプロピルメチルセルロース
のヒドロキシプロポキシ基のない場合)メトキシ基含量
31.2%、重量平均分子量5aoooo、Mw /M
N−4,4のメチルセルロース(信越化学■製)を生理
食塩水に溶解し、1゜8%の溶液を調製した。溶液の2
0℃における粘度は、10400cpsであった。この
溶液を0゜8μmのメンブレンフィルターで、3kg/
cm2の恒圧で濾過したところ、第3図に示す如く、濾
過回数を増やしても濾過性は全く向上せず、僅かな濾過
量で目詰まりを生じた。
Comparative Example 1 (Hydroxypropylmethylcellulose without hydroxypropoxy group) Methoxy group content 31.2%, weight average molecular weight 5aoooo, Mw /M
N-4,4 methyl cellulose (manufactured by Shin-Etsu Chemical Co., Ltd.) was dissolved in physiological saline to prepare a 1.8% solution. solution 2
The viscosity at 0°C was 10,400 cps. This solution was filtered through a 0°8 μm membrane filter at a rate of 3 kg/
When filtration was carried out under a constant pressure of cm2, as shown in FIG. 3, the filtration performance did not improve at all even if the number of filtration times was increased, and clogging occurred with a small amount of filtration.

比較例8 比較例7の濾液を実施例3と同様にして家兎眼の前房に
注入したところ、24時間後に炎症を発生し、48時間
後にも°回復しなかった。
Comparative Example 8 When the filtrate of Comparative Example 7 was injected into the anterior chamber of a rabbit eye in the same manner as in Example 3, inflammation occurred after 24 hours and did not recover even after 48 hours.

【図面の簡単な説明】 第1図は、実施例2にて調製したヒドロキシプロピルメ
チルセルロース溶液を0.8μmのメンブレンフィルタ
ーで3kg/Cl11gの恒圧で濾過したときの、各濾
過回数における、濾過量と流速との関係を示したグラフ
である。 第2図は、比較例3にて調製したヒドロキシプロピルメ
チルセルロース溶液を0.8μ麟のメンブレンフィルタ
ーで3kg/cm”の恒圧で濾過したときの、各濾過回
数における、濾過量と流速との関係を示したグラフであ
る。 第3図は、比較例7にて調製したメチルセルロース溶液
を0.8μmのメンブレンフィルターで3kg/c++
”の恒圧で濾過したときの、各濾過回数における、濾過
量と流速との関係を示したグラフである。
[Brief explanation of the drawings] Figure 1 shows the amount of filtration at each number of filtration times when the hydroxypropyl methylcellulose solution prepared in Example 2 was filtered with a 0.8 μm membrane filter at a constant pressure of 3 kg/11 g of Cl. It is a graph showing the relationship between the flow rate and the flow velocity. Figure 2 shows the relationship between filtration amount and flow rate at each filtration number when the hydroxypropyl methylcellulose solution prepared in Comparative Example 3 was filtered with a 0.8μ membrane filter at a constant pressure of 3kg/cm. Fig. 3 shows the methyl cellulose solution prepared in Comparative Example 7 filtered through a 0.8 μm membrane filter at 3 kg/c++.
It is a graph showing the relationship between the filtration amount and the flow rate at each number of filtration times when filtration is performed at a constant pressure of ``.

Claims (2)

【特許請求の範囲】[Claims] (1)メトキシ基含量28〜32%、ヒドロキシプロポ
キシ基含量7〜12%で、重量平均分子量(M_W)4
20000〜800000、数平均分子量(M_N)に
対する重量平均分子量の比(M_W/M_N)5.5以
下のヒドロキシプロピルメチルセルロースを次式に規定
される濃度範囲、 最大濃度の自然対数: logC_M_A_X=0.64−0.0055M最小
濃度の自然対数: logC_M_I_N=0.57−0.0071M(た
だし、C_M_A_Xはヒドロキシプロピルメチルセル
ロースの最大濃度(%)、C_M_I_Nはヒドロキシ
プロピルメチルセルロースの 最小濃度(%)、Mはヒドロキシプロピル メチルセルロースの「重量平均分子量× 10^−^4」を表す。) になるように塩類を含有する水に溶解した眼科手術用粘
弾性溶液。
(1) Methoxy group content 28-32%, hydroxypropoxy group content 7-12%, weight average molecular weight (M_W) 4
Hydroxypropyl methyl cellulose with a ratio of weight average molecular weight to number average molecular weight (M_N) (M_W/M_N) of 20,000 to 800,000 and 5.5 or less, within the concentration range defined by the following formula, natural logarithm of maximum concentration: logC_M_A_X = 0.64 -0.0055M Natural logarithm of the minimum concentration: logC_M_I_N=0.57-0.0071M (where, C_M_A_X is the maximum concentration (%) of hydroxypropyl methylcellulose, C_M_I_N is the minimum concentration (%) of hydroxypropyl methylcellulose, and M is hydroxypropyl A viscoelastic solution for ophthalmic surgery dissolved in water containing salts so that the weight average molecular weight of methylcellulose is x 10^-^4.
(2)ヒドロキシプロピルメチルセルロースの溶液濃度
がおよそ0.02%の場合において、電気抵抗法によっ
て測定した2μm以上の微粒子数が2500個/ml以
下、4μm以上の微粒子数が20個/ml以下である特
許請求の範囲第1項記載の眼科手術用粘弾性溶液。
(2) When the solution concentration of hydroxypropyl methyl cellulose is approximately 0.02%, the number of fine particles of 2 μm or more measured by electrical resistance method is 2500 particles/ml or less, and the number of fine particles of 4 μm or more is 20 particles/ml or less. A viscoelastic solution for ophthalmic surgery according to claim 1.
JP61110160A 1986-05-14 1986-05-14 Viscoelastic solution for ophthalmic surgery Expired - Lifetime JPH0657245B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP61110160A JPH0657245B2 (en) 1986-05-14 1986-05-14 Viscoelastic solution for ophthalmic surgery

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP61110160A JPH0657245B2 (en) 1986-05-14 1986-05-14 Viscoelastic solution for ophthalmic surgery

Publications (2)

Publication Number Publication Date
JPS62266056A true JPS62266056A (en) 1987-11-18
JPH0657245B2 JPH0657245B2 (en) 1994-08-03

Family

ID=14528569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61110160A Expired - Lifetime JPH0657245B2 (en) 1986-05-14 1986-05-14 Viscoelastic solution for ophthalmic surgery

Country Status (1)

Country Link
JP (1) JPH0657245B2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663851A1 (en) * 1990-06-29 1992-01-03 Mezhotraslevoi N Tekniches Agent for protecting the cornea and method for obtaining it
US5422376A (en) * 1993-04-30 1995-06-06 Webb; Bradford C. Synthetic viscoelastic material for ophthalmic applications
US5576306A (en) * 1991-03-01 1996-11-19 Dow Chemical Company Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers
US5585366A (en) * 1991-03-08 1996-12-17 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
JP2004530456A (en) * 2000-12-20 2004-10-07 アルコン、インコーポレイテッド Solution for removing cataract by liquefaction destruction

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663851A1 (en) * 1990-06-29 1992-01-03 Mezhotraslevoi N Tekniches Agent for protecting the cornea and method for obtaining it
GB2246353A (en) * 1990-06-29 1992-01-29 Mezhotraslevoi Nt Komplex Mikr Cornea-protecting compositions
US5576306A (en) * 1991-03-01 1996-11-19 Dow Chemical Company Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers
US5585366A (en) * 1991-03-08 1996-12-17 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
US5422376A (en) * 1993-04-30 1995-06-06 Webb; Bradford C. Synthetic viscoelastic material for ophthalmic applications
USRE42243E1 (en) 1993-04-30 2011-03-22 Alcon, Inc. Synthetic viscoelastic material for ophthalmic applications
JP2004530456A (en) * 2000-12-20 2004-10-07 アルコン、インコーポレイテッド Solution for removing cataract by liquefaction destruction

Also Published As

Publication number Publication date
JPH0657245B2 (en) 1994-08-03

Similar Documents

Publication Publication Date Title
US4819617A (en) Viscoelastic material for ophthalmic surgery
CA1338509C (en) Viscoelastic material for ophthalmic surgery
EP1854812B1 (en) Pectic polysaccharides isolated from fruit pods of okra
KR100246016B1 (en) Synthetic viscoelastic material for ophthalmic applications
Miller et al. Use of Na-hyaluronate during intraocular lens implantation in rabbits
CN103110575B (en) Meloxicam eye drop as well as preparation method and application thereof
CA2282757C (en) Opthalmic composition
JPS62266056A (en) Viscoelastic solution for ophthalmic operation
JP2007525515A (en) Alginate viscoelastic composition, method of use and package
JP4169596B2 (en) Solution for removing cataracts by liquefaction destruction
WO1999026637A1 (en) Ophthalmic preparation and ophthalmic composition
JP2005502581A (en) Intraocular perfusion solution with improved flow characteristics
WO2003059391A2 (en) Viscoelastics for ocular surgery
JP2004530452A (en) Non-attractable transition viscoelastic materials for use in surgery
Tandon 26 Chapter Viscoelastic Substances (Ophthalmic Viscosurgical Devices)
JP3174400B2 (en) Peritoneal washings
JPS61220651A (en) Ophthalmic injection solution
CN110404111A (en) Dual crosslinking artificial vitreous of high cohesion and preparation method thereof
AU2018372826B2 (en) Ophthalmic viscoelastic compositions
RU2086217C1 (en) Corneal endothelium protection means for applying emergency ophthalmosurgery
WO2024040480A1 (en) Gel material and preparation method therefor
JP5416688B2 (en) Composition with reduced viscosity prevention
JPH06199656A (en) Method for removing pyrogen
Greiner 28 Viscoelastics
JPH03215269A (en) Material for intraocular lens